Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Biontech, Chugai, Direct Biologics, Genentech, HDT, Hutchmed, Ildong, Innocare, Innovent, Junshi, Lupin, Moderna, Pfizer, Roche, Solasia, Yiling.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Aditum, Amyris, Ancora, Astrazeneca, Biophytis, Clover, Codagenix, Dynavax Technologies, Endo International, Glaxosmithkline, Nant Africa, Oyster Point, PYC, Quanta, Simcere, Taisho, TLC, Vir, Vivoryon.
Just five days after raising $105 million in a series E financing round, RNA interference therapeutics specialist Sirnaomics Inc. obtained another IND approval from the FDA for its dual-targeting small interfering RNA (siRNA) inhibitor STP-707 to start a basket study in oncology. Sirnaomics’ CEO Patrick Lu told BioWorld in an exclusive interview that an I.V. administration of STP-707 will be tested to tackle solid cancers that may have metastasized into other potential areas or tissue types in the body.
Data presented at The International Liver Congress – The Annual Meeting of the European Association for the Study of the Liver, including: Brii Biosciences, VBI Vaccines.